AGIO Agios Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Tem 30, 2026
$31,80
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$22,2452 haftanın en düşüğü
$46,0052 haftanın en yükseği
Piyasa Değeri (MRQ)
$1.90B
P/E (TTM)
-4.5
Hisse Başına Kâr (TTM)
$-7.02
Gelir (TTM)
$98M
rozetleriniz
52 Haftlık Aralık
$22–$46
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$46
P/E
-4.5
ROE
-34.3%
Net Kâr Marjı
-418.2%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
AGIO Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$31.80
Piyasa Değeri (MRQ)
$1.90B
P/E (TTM)
-4.5
Hisse Başına Kâr (TTM)
$-7.02
Gelir (TTM)
$98M
ROE (TTM)
-34.3%
52 Haftlık Aralık
$22–$46
AGIO Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Agios Pharmaceuticals, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
History
In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.
In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120 million in drug licensing payments.
In April 2017, the company raised $250 million in a new stock offering in anticipation of approval for its first cancer drug, enasidenib, by the US Food and Drug Administration.
In December 2017, the company filed a New Drug Application with the US FDA for ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
In November 2019, Agios announced an underwritten public offering of 8,250,000 shares of common stock at a price of $31.00 per share which would result in approximately $256 million aggregate gross proceeds.
In April 2022, the FDA approved mitapivat as first disease-modifying therapy for hemolytic anemia in adults with pyruvate kinase deficiency.
Corporate governance
As of August 2022, Agios' CEO is Brian Goff.
Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar539
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$54M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-7.122019-12-31 → 2025-12-31
Serbest Nakit Akışı$-377M2016-12-31 → 2025-12-31
Net kar marjı-418.2%2017-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | AGIO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -4.55Y ort. ≈-2.0 | ≈-2.0 | · | · | |
| F/S (TTM) | 19.35Y ort. ≈59.0 | ≈59.0 | 25.9 | Adil değer | |
| F/D (MRQ) | 1.85Y ort. ≈1.4 | ≈1.4 | 6.0 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | -5.25Y ort. ≈-4.5 | ≈-4.5 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -5.35Y ort. ≈-4.5 | ≈-4.5 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 2013.95Y ort. ≈1.4 | ≈1.4 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | AGIO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -466.8%5Y ort. ≈-1558.0% | ≈-1558.0% | -474.4% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | -873.9%5Y ort. ≈-1558.0% | ≈-1558.0% | -474.4% | En üst düzey | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | -765.9%5Y ort. ≈-434.8% | ≈-434.8% | -660.8% | Zayıf | |
| Net Kâr Marjı (TTM) | -418.2%5Y ort. ≈-464.6% | ≈-464.6% | -442.9% | En üst düzey | |
| ROA (TTM) | -31.9%5Y ort. ≈22.9% | ≈22.9% | -34.8% | En üst düzey | |
| ROE (TTM) | -34.3%5Y ort. ≈13.4% | ≈13.4% | -76.5% | En üst düzey | |
| ROIC | -39.5% | · | -134.2% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | AGIO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 10.25Y ort. ≈13.3 | ≈13.3 | 7.7 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 1.15Y ort. ≈1.8 | ≈1.8 | 4.3 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | AGIO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 48.0%5Y ort. ≈57.5% | ≈57.5% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 56.0% | · | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | -24.0% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | -25.1% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | AGIO | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.0 | ≈0.0 | 0.3 | Zayıf | |
| Inventory Turnover (Stok Devir Hızı) | 0.25Y ort. ≈0.2 | ≈0.2 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$100.2K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
5.5%
Sonraki Rapor
Eki 28, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Tem 29, 2026 | $-1.69 | $-1.70 | 0.66% |
| 31 Mart 2026 | $-1.69 | $-1.84 | 8.0% | |
| 31 Aralık 2025 | $-1.86 | $-1.99 | 6.3% | |
| 30 Eylül 2025 | $-1.78 | $-1.94 | 8.1% | |
| 30 Haziran 2025 | $-1.93 | $-1.84 | -4.7% | |
| 31 Mart 2025 | $-1.55 | $-1.82 | 14.8% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Cost of Revenue | $6M | $4M | $3M | $2M | $0 | $0 | $1M | $1M | $0 | $0 | · | · | |
| R&D Expense | $340M | $301M | $296M | $280M | $257M | $221M | $214M | $341M | $293M | $220M | $142M | $100M | |
| SG&A Expense | $180M | $157M | $120M | $122M | $121M | $115M | $102M | $114M | $71M | $51M | $36M | $19M | |
| Operating Expenses | $526M | $462M | $418M | $403M | $378M | $336M | $316M | $457M | $364M | $271M | $178M | $119M | |
| Operating Income | $-472M | $-426M | $-391M | $-389M | $-378M | $-336M | $-316M | $-362M | $-321M | $-201M | $-119M | $-54M | |
| Interest Income | · | · | · | $13M | $836.0K | $7M | $15M | $16M | $6M | $3M | $968.0K | $203.0K | |
| Other Non-op | $2M | $6M | $6M | $7M | $14M | $0 | $0 | · | · | · | · | · | |
| Pretax Income | $-414M | $718M | $-352M | $-232M | $-357M | $-329M | $-301M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Income Tax | $-1M | $44M | $0 | $0 | · | · | $0 | $0 | $0 | $0 | $0 | $-426.0K | |
| Net Income | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | · | |
| Shares (Basic) | 57,972,004 | 56,807,415 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| Shares (Diluted) | 57,972,004 | 57,889,255 | 55,651,487 | 54,789,435 | 60,447,346 | 68,997,879 | 59,994,539 | · | · | · | · | · | |
| EBITDA | $-472M | $-426M | $-391M | $-389M | $-378M | $-316M | $-418M | $-362M | $-321M | $-201M | $-119M | $-54M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $89M | $76M | $88M | $139M | $203M | $127M | $81M | $71M | $103M | $161M | $72M | $14M | |
| Short-term Investments | · | · | · | · | · | · | · | $515M | $321M | $381M | · | · | |
| Inventory | $33M | $28M | $19M | $8M | $0 | $15M | $7M | $869.0K | $0 | · | · | · | |
| Prepaid Expense | $44M | $40M | $35M | $39M | $40M | $16M | $24M | $17M | $18M | $10M | $9M | $5M | |
| Current Assets | $942M | $966M | $834M | $833M | $1.06B | $637M | $612M | $614M | $445M | $560M | $337M | $360M | |
| PP&E (Net) | $11M | $12M | $15M | $23M | $29M | $31M | $31M | $24M | $24M | $25M | $23M | $6M | |
| PP&E (Gross) | $71M | $68M | $68M | $73M | $74M | $72M | $64M | $50M | $44M | $39M | $31M | $12M | |
| Accum. Depreciation | $60M | $56M | $52M | $50M | $45M | $41M | $32M | $26M | $19M | $13M | $8M | $6M | |
| Other Non-current Assets | $4M | $5M | $4M | $4M | $3M | $0 | $0 | $238.0K | $891.0K | $2M | $611.0K | $590.0K | |
| Total Assets | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Accounts Payable | $18M | $17M | $10M | $19M | $17M | $18M | $22M | $18M | $23M | $17M | $15M | $11M | |
| Accrued Liabilities | $45M | $47M | $43M | $30M | $32M | $31M | $53M | $42M | $34M | $32M | $16M | $14M | |
| Current Liabilities | $82M | $81M | $68M | $63M | $60M | $94M | $93M | $94M | $95M | $88M | $53M | $61M | |
| Capital Leases | $22M | $40M | $57M | $72M | $86M | $97M | $106M | · | · | · | · | · | |
| Other Non-current Liabilities | $90.0K | $880.0K | $1M | $3M | $0 | · | · | · | · | · | · | · | |
| Total Liabilities | $104M | $122M | $126M | $138M | $146M | $453M | $250M | $171M | $239M | $261M | · | · | |
| Common Stock | · | · | · | · | $71.0K | $69.0K | $68.0K | $58.0K | $49.0K | $42.0K | $38.0K | $37.0K | |
| Retained Earnings | $-562M | $-149M | $-823M | $-471M | $-239M | $-1.84B | $-1.52B | $-1.10B | $-798M | $-483M | $-285M | $-167M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $0 | · | · | · | · | · | · | |
| Stockholders' Equity | $1.19B | $1.54B | $811M | $1.10B | $1.29B | $400M | $641M | $688M | $376M | $359M | $345M | $424M | |
| Liabilities + Equity | $1.30B | $1.66B | $937M | $1.24B | $1.44B | $853M | $891M | $858M | $614M | $619M | $420M | $492M | |
| Shares Outstanding | 58,448,592 | 73,372,696,000 | 72,161,489 | 71,256,118 | 70,550,631 | 69,293,920 | 68,401,105 | 58,218,653 | 48,826,153 | 42,220,444 | 37,696,502 | 37,100,513 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | $8M | $7M | $6M | · | · | · | |
| Stock-based Comp | $53M | $43M | $45M | $49M | $54M | $62M | $58M | $73M | $48M | $42M | $32M | $12M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Other Non-cash | · | · | · | · | · | · | $-40M | · | · | · | · | · | |
| Operating Cash Flow | $-373M | $-390M | $-296M | $-309M | $-407M | $-291M | $-371M | $-304M | $-285M | $39M | $-77M | $-59M | |
| CapEx | $4M | $2M | $999.0K | $5M | $6M | $14M | $12M | $7M | $5M | $10M | $20M | $2M | |
| Investing Cash Flow | $377M | $363M | $240M | $243M | $1.25B | $76M | $91M | $-274M | $-58M | $-119M | $128M | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | $0 | $334M | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $277M | $516M | $270M | $162M | · | $334M | |
| Financing Cash Flow | $9M | $14M | $5M | $2M | $-766M | $262M | $290M | $546M | $285M | $170M | $6M | · | |
| Net Change in Cash | $13M | $-12M | $-51M | $-64M | $76M | $47M | $10M | $-32M | $-58M | $89M | $58M | $-58M | |
| Taxes Paid | $628.0K | $43M | $2M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-377M | $-392M | $-297M | $-314M | $-413M | $-306M | $-383M | $-311M | $-290M | $29M | $-97M | $-62M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -361.6% | · | -745.8% | · | · | -82.8% | |
| Net Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | · | -161.1% | -349.0% | · | -731.6% | · | · | -81.9% | |
| Pretax Margin | -765.9% | 1967.2% | -1312.6% | -1627.8% | · | -161.2% | -349.0% | · | -731.6% | · | · | -82.5% | |
| EBITDA Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | · | -155.6% | -354.7% | · | -745.8% | · | · | -82.8% | |
| ROA | -27.9% | 51.8% | -32.4% | -17.3% | 140.1% | -37.5% | -47.0% | -47.0% | -51.0% | -38.2% | -25.8% | -15.4% | |
| ROE | -32.2% | 42.5% | -41.5% | -21.6% | 119.4% | -74.4% | -75.6% | -47.8% | -85.7% | -56.4% | -30.6% | -19.2% | |
| ROIC | -39.5% | -25.9% | · | · | · | · | -66.6% | -52.7% | -85.4% | · | · | -12.7% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 | 6.7 | 6.6 | 6.6 | 4.7 | 6.3 | 6.4 | 5.9 | |
| Quick Ratio | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 | 1.4 | 0.9 | 6.3 | 4.5 | 1.8 | 1.4 | 0.2 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.2 | 0.1 | · | 0.1 | · | · | 0.2 | |
| Inventory Turnover | 0.2 | 0.2 | 0.2 | 0.4 | · | 0.3 | 0.3 | 3.2 | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.41 | $26.96 | $14.50 | $20.00 | $23.78 | $5.77 | $9.36 | $11.81 | $7.69 | $8.49 | $9.16 | $11.44 | |
| Revenue / Share | $0.93 | $0.63 | $0.48 | $0.26 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-6.43 | $-6.73 | $-5.32 | $-5.65 | $-6.74 | · | · | · | · | · | · | · | |
| Cash / Share | $1.52 | $1.33 | $1.58 | $2.53 | $3.74 | $1.84 | $1.18 | $1.21 | $2.10 | $3.81 | $1.90 | $0.38 | |
| EPS (TTM) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | · | · | · | · | $-1.59 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 48.0% | 36.1% | 88.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 56.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -24.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -25.1% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $36M | $27M | $14M | $0 | $0 | $118M | $94M | $43M | $70M | $59M | $65M | |
| Net Income TTM | $-413M | $674M | $-352M | $-232M | $1.60B | $-327M | $-411M | $-346M | $-315M | $-198M | $-118M | $-54M | |
| Market Cap | $1.59B | $1.88B | $1.25B | $1.55B | $1.79B | $3.00B | $3.27B | $2.68B | $2.79B | $1.76B | $2.45B | $4.16B | |
| P/E | -3.8 | 2.8 | -3.5 | -6.6 | 1.2 | -9.1 | -7.0 | · | · | · | · | -70.5 | |
| P/S | 29.4 | 51.5 | 46.4 | 108.5 | · | · | 27.7 | 28.4 | 64.9 | 25.2 | 41.4 | 63.6 | |
| P/B | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | 5.1 | 3.9 | 7.4 | 4.9 | 7.1 | 9.8 | |
| P / Tangible Book | 1.3 | 1.2 | 1.5 | 1.4 | 1.4 | 7.5 | · | · | · | · | · | · | |
| P / Cash Flow | -4.3 | -4.8 | -4.2 | -5.0 | -4.4 | -10.3 | -8.8 | -8.8 | -9.8 | 45.7 | -31.8 | -70.0 | |
| P / FCF | -4.2 | -4.8 | -4.2 | -4.9 | -4.3 | -9.8 | -8.5 | -8.6 | -9.6 | 61.5 | -25.2 | -67.5 | |
| Earnings Yield | -26.2% | 35.4% | -28.4% | -15.1% | 80.8% | -10.9% | -14.4% | · | · | · | · | -1.4% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $21M | $20M | $13M | $12M | $9M | $11M | $9M | $9M | $8M | $7M | $7M | $7M | $6M | $4M | $4M | |
| Cost of Revenue | $3M | $1M | $2M | $2M | $2M | $1M | $1M | $783.0K | $1M | $627.0K | $586.0K | $633.0K | $1M | $554.0K | $413.0K | $517.0K | |
| R&D Expense | $101M | $81M | $88M | $87M | $92M | $73M | $83M | $72M | $77M | $69M | $77M | $82M | $69M | $67M | $70M | $65M | |
| SG&A Expense | $52M | $48M | $52M | $41M | $46M | $42M | $52M | $39M | $36M | $31M | $35M | $26M | $30M | $28M | $33M | $29M | |
| Operating Expenses | $155M | $131M | $142M | $130M | $140M | $115M | $136M | $112M | $114M | $100M | $113M | $108M | $100M | $96M | $103M | $95M | |
| Operating Income | $-111M | $-110M | $-122M | $-117M | $-127M | $-107M | $-125M | $-103M | $-106M | $-92M | $-106M | $-101M | $-94M | $-91M | $-99M | $-91M | |
| Other Non-op | $119.0K | $119.0K | $113.0K | $67.0K | $523.0K | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $1M | $1M | |
| Pretax Income | · | · | $-109M | $-103M | · | · | $-105M | $1.00B | · | · | $-96M | $-91M | · | · | · | · | |
| Income Tax | · | · | $-1M | $0 | · | · | $-9M | $53M | · | · | $0 | $0 | · | · | $0 | $0 | |
| Net Income | $-101M | $-99M | $-108M | $-103M | $-112M | $-89M | $-97M | $948M | $-96M | $-82M | $-96M | $-91M | $-84M | $-81M | $37M | $-82M | |
| EPS (Basic) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.65 | $16.65 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| EPS (Diluted) | $-1.69 | $-1.69 | $-1.86 | $-1.78 | $-1.93 | $-1.55 | $-1.44 | $16.22 | $-1.69 | $-1.45 | $-1.71 | $-1.64 | $-1.51 | $-1.47 | $0.68 | $-1.49 | |
| Shares (Basic) | 59,488,871 | 58,782,241 | · | 58,139,277 | 57,932,576 | 57,459,195 | · | 56,939,403 | 56,802,546 | 56,383,475 | · | 55,803,663 | 55,604,330 | 55,265,390 | · | 54,844,579 | |
| Shares (Diluted) | 59,488,871 | 58,782,241 | · | 58,139,277 | 57,932,576 | 57,459,195 | · | 58,432,796 | 56,802,546 | 56,383,475 | · | 55,803,663 | 55,604,330 | 55,265,390 | · | 54,844,579 | |
| EBITDA | $-111M | $-110M | · | $-117M | $-127M | $-107M | · | $-103M | $-106M | $-92M | · | $-101M | $-94M | $-91M | · | $-91M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $100M | $114M | $89M | $93M | $81M | $79M | $76M | $254M | $85M | $119M | · | $64M | $85M | $104M | · | $122M | |
| Inventory | $36M | $35M | $33M | $32M | $31M | $30M | $28M | $26M | $24M | $23M | · | $17M | $16M | $11M | · | $5M | |
| Prepaid Expense | $46M | $47M | $44M | $43M | $45M | $42M | $40M | $40M | $35M | $39M | · | $38M | $37M | $39M | · | $46M | |
| Current Assets | $718M | $835M | $942M | $1.03B | $1.02B | $969M | $966M | $1.07B | $632M | $664M | · | $704M | $757M | $792M | · | $785M | |
| PP&E (Net) | $10M | $11M | $11M | $11M | $11M | $11M | $12M | $12M | $13M | $14M | · | $17M | $20M | $21M | · | $25M | |
| PP&E (Gross) | · | · | $71M | · | · | · | $68M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $60M | · | · | · | $56M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $10M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $4M | · | $4M | $4M | $4M | · | $4M | |
| Total Assets | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Accounts Payable | $16M | $14M | $18M | $20M | $18M | $14M | $17M | $17M | $10M | $11M | · | $13M | $12M | $9M | · | $10M | |
| Accrued Liabilities | $35M | $26M | $45M | $37M | $35M | $21M | $47M | $33M | $37M | $25M | · | $30M | $29M | $22M | · | $30M | |
| Current Liabilities | $70M | $59M | $82M | $75M | $70M | $52M | $81M | $119M | $63M | $52M | · | $58M | $55M | $45M | · | $54M | |
| Capital Leases | $12M | $17M | $22M | $27M | $31M | $36M | $40M | $45M | $49M | $53M | · | $61M | $65M | $68M | · | $75M | |
| Other Non-current Liabilities | $240.0K | $90.0K | $90.0K | $90.0K | $101.0K | $880.0K | $880.0K | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Total Liabilities | $82M | $76M | $104M | $101M | $102M | $89M | $122M | $165M | $113M | $106M | · | $120M | $121M | $115M | · | $130M | |
| Retained Earnings | $-762M | $-661M | $-562M | $-454M | $-350M | $-238M | $-149M | $-52M | $-1.00B | $-904M | · | $-727M | $-635M | $-552M | · | $-507M | |
| Treasury Stock | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | $802M | · | $802M | $802M | $802M | · | $802M | |
| Stockholders' Equity | $1.03B | $1.11B | $1.19B | $1.28B | $1.37B | $1.47B | $1.54B | $1.63B | $661M | $744M | $811M | $887M | $964M | $1.04B | $1.10B | $1.05B | |
| Liabilities + Equity | $1.11B | $1.18B | $1.30B | $1.39B | $1.47B | $1.56B | $1.66B | $1.79B | $773M | $850M | · | $1.01B | $1.09B | $1.15B | · | $1.18B | |
| Shares Outstanding | 59,604,830 | 59,341,338 | 58,448,592 | 58,279,876 | 58,038,545 | 57,886,781 | 57,156,285 | 57,021,543 | 56,875,079 | 56,751,511 | 72,161,489 | 55,883,973 | 55,734,775 | 55,541,367 | 71,256,118 | 54,894,031 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $16M | $16M | $14M | $12M | $15M | $11M | $11M | $11M | $12M | $9M | $14M | $9M | $12M | $10M | $11M | $11M | |
| Operating Cash Flow | $-57M | $-119M | $-96M | $-88M | $-77M | $-111M | $-133M | $-84M | $-73M | $-100M | $-72M | $-62M | $-67M | $-95M | $-66M | $-71M | |
| CapEx | $1M | $769.0K | $1M | $2M | $875.0K | $766.0K | $967.0K | $419.0K | $158.0K | $141.0K | $234.0K | $369.0K | $-3.0K | $399.0K | $113.0K | $38.0K | |
| Investing Cash Flow | $40M | $141M | $90M | $96M | $79M | $113M | $-49M | $251M | $37M | $125M | $96M | $39M | $47M | $58M | $83M | $104M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Financing Cash Flow | $3M | $2M | $3M | $4M | $65.0K | $2M | $5M | $3M | $1M | $6M | $847.0K | $2M | $237.0K | $2M | $22.0K | $1M | |
| Net Change in Cash | $-14M | $24M | $-4M | $12M | $2M | $3M | $-177M | $169M | $-34M | $31M | $24M | $-20M | $-19M | $-35M | $17M | $34M | |
| Taxes Paid | $70.0K | $4.0K | $-940.0K | $65.0K | $1M | $188.0K | $44M | $-34.0K | $-78.0K | $-525.0K | $-17.0K | $785.0K | $801.0K | $0 | · | $98.0K | |
| Free Cash Flow | · | $-120M | · | · | · | $-112M | · | · | · | $-100M | · | · | · | $-96M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| Net Margin | -225.1% | -477.7% | · | -803.0% | -899.4% | -1023.2% | · | 10574.7% | -1115.7% | -995.8% | · | -1234.3% | -1248.6% | -1444.4% | · | -2325.0% | |
| Pretax Margin | · | · | · | -803.0% | · | · | · | 11167.3% | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -247.1% | -530.3% | · | -907.4% | -1020.1% | -1222.0% | · | -1146.9% | -1228.3% | -1124.3% | · | -1363.7% | -1396.0% | -1615.5% | · | -2590.7% | |
| ROA | -7.8% | -7.2% | · | -6.5% | -10.0% | -7.4% | · | 67.7% | -10.3% | -8.2% | · | -8.3% | -7.2% | -6.5% | · | -6.0% | |
| ROE | -8.4% | -7.7% | · | -7.1% | -11.0% | -8.1% | · | 75.4% | -11.8% | -9.2% | · | -9.4% | -8.0% | -7.2% | · | -6.7% | |
| ROIC | · | · | · | -9.1% | · | · | · | -6.0% | · | · | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.2 | 14.2 | · | 13.8 | 14.5 | 18.5 | · | 9.0 | 10.1 | 12.8 | · | 12.1 | 13.7 | 17.5 | · | 14.6 | |
| Quick Ratio | 1.4 | 1.9 | · | 1.2 | 1.1 | 1.5 | · | 2.1 | 1.3 | 2.3 | · | 1.1 | 1.5 | 2.3 | · | 2.3 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $17.21 | $18.69 | · | $22.04 | $23.60 | $25.33 | · | $28.53 | $11.61 | $13.11 | · | $15.87 | $17.30 | $18.66 | · | $19.13 | |
| Revenue / Share | $0.75 | $0.35 | · | $0.22 | $0.21 | $0.15 | · | $0.15 | $0.15 | $0.15 | · | $0.13 | $0.12 | $0.10 | · | $0.06 | |
| Cash Flow / Share | · | $-2.02 | · | · | · | $-1.94 | · | · | · | $-1.77 | · | · | · | $-1.72 | · | · | |
| Cash / Share | $1.67 | $1.91 | · | $1.59 | $1.39 | $1.36 | · | $4.45 | $1.49 | $2.09 | · | $1.15 | $1.52 | $1.88 | · | $2.23 | |
| EPS (TTM) | $-7.02 | $-7.26 | · | $-6.70 | $11.30 | $11.54 | · | $11.37 | $-6.49 | $-6.31 | · | $-3.94 | $-3.79 | $-3.96 | · | $-2.34 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $98M | $66M | · | $45M | $41M | $37M | · | $33M | $31M | $29M | · | $24M | $20M | $19M | · | $10M | |
| Net Income TTM | $-411M | $-423M | · | $-401M | $650M | $666M | · | $674M | $-365M | $-353M | · | $-220M | $-210M | $-218M | · | $-363M | |
| Market Cap | $2.21B | $2.01B | · | $2.34B | $1.93B | $1.70B | · | $2.53B | $2.45B | $1.66B | · | $1.38B | $1.58B | $1.28B | · | $1.55B | |
| P/E | -5.3 | -4.7 | · | -6.0 | 2.9 | 2.5 | · | 3.9 | -6.6 | -4.6 | · | -6.3 | -7.5 | -5.8 | · | -12.1 | |
| P/S | 22.5 | 30.4 | · | 52.2 | 47.2 | 45.8 | · | 77.1 | 78.3 | 56.4 | · | 57.6 | 78.3 | 67.1 | · | 156.3 | |
| P/B | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Tangible Book | 2.2 | 1.8 | · | 1.8 | 1.4 | 1.2 | · | 1.6 | 3.7 | 2.2 | · | 1.6 | 1.6 | 1.2 | · | 1.5 | |
| P / Cash Flow | · | -16.9 | · | · | · | -15.2 | · | · | · | -16.6 | · | · | · | -13.4 | · | · | |
| Earnings Yield | -18.9% | -21.5% | · | -16.7% | 34.0% | 39.4% | · | 25.6% | -15.0% | -21.6% | · | -15.9% | -13.4% | -17.2% | · | -8.3% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $54M | $36M | $27M | $14M | $0 |
| Faaliyet Kâr Marjı % | -873.9% | -1166.5% | -1459.5% | -2732.1% | · |
| Net Gelir | $-413M | $674M | $-352M | $-232M | $1.60B |
| Seyreltilmiş Hisse Başı Kâr | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 11.5 | 11.9 | 12.3 | 13.3 | 17.8 |
| Cari Oran | 1.1 | 0.9 | 1.3 | 2.2 | 3.4 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-377M | $-392M | $-297M | $-314M | $-413M |
Kurumsal Sahipler (13F) 262 dosya · $2.7B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
262
Tutulan Değer
$2.7B
Yeni pozisyonlar
39
Çıkan pozisyonlar
30
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 39 (-2 önceki Ç'ye göre) | 30 (-2 önceki Ç'ye göre) | 96 (+16 önceki Ç'ye göre) | 69 (-19 önceki Ç'ye göre) | +8.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $239.582.050 | 6.455.997 | 8,88% | Hisse senetleri |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $219.594.714 | 5.917.400 | 8,14% | Hisse senetleri |
| VANGUARD GROUP INC | $152.278.288 | 5.594.353 | 5,64% | Hisse senetleri |
| STATE STREET CORP | $131.144.972 | 3.533.633 | 4,86% | Hisse senetleri |
| Lynx1 Capital Management LP | $126.505.652 | 3.408.937 | 4,69% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $115.300.956 | 3.107.005 | 4,27% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $107.552.091 | 2.898.197 | 3,98% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $104.279.100 | 2.810.000 | 3,86% | Alım opsiyonu |
| VANGUARD CAPITAL MANAGEMENT LLC | $99.523.268 | 2.681.845 | 3,69% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $89.064.000 | 2.400.000 | 3,30% | Hisse senetleri |
| Erste Asset Management GmbH | $81.972.396 | 2.154.900 | 3,04% | Hisse senetleri |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $78.332.000 | 2.110.809 | 2,90% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $58.433.490 | 1.574.268 | 2,17% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $51.046.957 | 1.375.558 | 1,89% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $47.799.647 | 1.288.053 | 1,77% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47.502.433 | 1.280.044 | 1,76% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $46.345.467 | 1.248.738 | 1,72% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $42.711.087 | 1.150.932 | 1,58% | Hisse senetleri |
| UBS Group AG | $36.584.189 | 985.831 | 1,36% | Hisse senetleri |
| MORGAN STANLEY | $35.746.487 | 963.256 | 1,32% | Hisse senetleri |
| Nuveen, LLC | $32.417.811 | 873.560 | 1,20% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $30.078.768 | 810.530 | 1,11% | Hisse senetleri |
| Foresite Capital Management VI LLC | $29.131.350 | 785.000 | 1,08% | Hisse senetleri |
| CITADEL ADVISORS LLC | $27.190.015 | 732.687 | 1,01% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $25.395.858 | 684.340 | 0,94% | Hisse senetleri |
| Parkman Healthcare Partners LLC | $24.828.297 | 669.046 | 0,92% | Hisse senetleri |
| SCS Capital Management LLC | $22.742.864 | 612.850 | 0,84% | Hisse senetleri |
| Qube Research & Technologies Ltd | $22.178.346 | 597.638 | 0,82% | Hisse senetleri |
| NORTHERN TRUST CORP | $20.585.250 | 554.709 | 0,76% | Hisse senetleri |
| Defilade Capital Management, L.P. | $20.293.529 | 546.848 | 0,75% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.969.930 | 538.128 | 0,74% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $19.905.062 | 536.380 | 0,74% | Hisse senetleri |
| Rock Springs Capital Management LP | $19.763.413 | 532.563 | 0,73% | Hisse senetleri |
| Schonfeld Strategic Advisors LLC | $19.300.279 | 520.083 | 0,72% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $18.847.034 | 507.869 | 0,70% | Hisse senetleri |
| Point72 Asset Management, L.P. | $18.790.426 | 506.344 | 0,70% | Hisse senetleri |
| JANE STREET GROUP, LLC | $18.280.312 | 492.598 | 0,68% | Hisse senetleri |
| Legal & General Group Plc | $16.132.422 | 434.719 | 0,60% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $14.690.661 | 395.868 | 0,54% | Hisse senetleri |
| PANAGORA ASSET MANAGEMENT INC | $13.876.579 | 373.931 | 0,51% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.850.565 | 373.230 | 0,51% | Hisse senetleri |
| JPMORGAN CHASE & CO | $13.783.528 | 359.756 | 0,51% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $13.342.901 | 359.550 | 0,49% | Hisse senetleri |
| Squarepoint Ops LLC | $11.917.431 | 321.138 | 0,44% | Hisse senetleri |
| Ensign Peak Advisors, Inc | $11.045.049 | 297.630 | 0,41% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $9.996.803 | 269.383 | 0,37% | Hisse senetleri |
| ALGERT GLOBAL LLC | $9.203.540 | 248.007 | 0,34% | Hisse senetleri |
| JANE STREET GROUP, LLC | $7.974.939 | 214.900 | 0,30% | Satım opsiyonu |
| Palo Alto Investors LP | $7.926.733 | 213.601 | 0,29% | Hisse senetleri |
| Tetragon Partners GP Ltd | $7.629.037 | 205.579 | 0,28% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION, CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC | 05 Nisan 2021 | · | İlk başvuru | · | SEC |
| CELGENE SWITZERLAND LLC, CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 başvurular | 14 Kasım 2019 | · | İlk başvuru | Sermaye yapısı | SEC |
| CELGENE EUROPEAN INVESTMENT COMPANY LLC, CELGENE ALPINE INVESTMENT CO., LLC, CELGENE CORPORATION ×3 başvurular | 17 Aralık 2014 | · | İlk başvuru | Sermaye yapısı | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 38 içeriden öğrenenler · 18 yöneticiler · 20 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Brian Goff | Chief Executive Officer | 18 Haziran 2026 A | 184.508 | 0 | 7 | $-1.691.387 |
| Cecilia Jones | Chief Financial Officer | 18 Haziran 2026 A | 54.998 | 0 | 6 | $-334.266 |
| Jonathan Biller | Chief Financial Officer | 01 Mart 2022 A | 22.953 | 0 | 0 | $0 |
| Andrew Hirsch | Chief Financial Officer | 22 Nisan 2020 M | 24.272 | 0 | 0 | $0 |
| John Duncan Higgons | Chief Operating Officer | 04 Ocak 2016 M | 120.834 | 0 | 0 | $0 |
| Sarah Gheuens | Chief Medical Officer | 04 Ağustos 2026 S | 54.645 | 0 | 10 | $-1.625.034 |
| Krishnan Viswanadhan | Chief Strategy and Operations | 18 Haziran 2026 A | 10.282 | 0 | 2 | $-184.967 |
| Tsveta Milanova | Chief Commercial Officer | 18 Haziran 2026 A | 46.829 | 0 | 5 | $-353.311 |
| James William Burns | Chief Legal Officer | 18 Haziran 2026 A | 49.306 | 0 | 6 | $-344.391 |
| Theodore James Washburn Jr. | Principal Accounting Officer | 03 Mart 2026 S | 868 | 0 | 4 | $-216.633 |
| Richa Poddar | Chief Commercial Officer | 15 Ekim 2022 M | 8.508 | 0 | 0 | $0 |
| Bruce Car | Chief Scientific Officer | 01 Mart 2022 A | 16.752 | 0 | 0 | $0 |
| Carman Alenson | Principal Accounting Officer | 21 Haziran 2021 M | 0 | 0 | 0 | $0 |
| Christopher Bowden | Chief Medical Officer | 18 Haziran 2021 M | 15.487 | 0 | 0 | $0 |
| Darrin Miles | Chief Commercial Officer | 14 Mayıs 2021 S | 7.209 | 0 | 0 | $0 |
| Scott Biller | Chief Scientific Officer | 11 Haziran 2019 M | 33.729 | 0 | 0 | $0 |
| Steven L. Hoerter | Chief Commercial Officer | 04 Mart 2019 M | 10.941 | 0 | 0 | $0 |
| Glenn Goddard | Senior Vice President, Finance | 16 Şubat 2016 A | 0 | 0 | 0 | $0 |
| Jay T. Backstrom | Yönetim kurulu üyesi | 08 Temmuz 2026 M | 1.447 | 0 | 0 | $0 |
| Adams Catherine Owen | Yönetim kurulu üyesi | 18 Haziran 2026 A | 10.865 | 0 | 0 | $0 |
| Rahul D. Ballal | Yönetim kurulu üyesi | 18 Haziran 2026 A | 15.230 | 0 | 0 | $0 |
| David Scadden | Yönetim kurulu üyesi | 18 Haziran 2026 A | 20.419 | 0 | 2 | $-16.968 |
| Maykin Ho | Yönetim kurulu üyesi | 18 Haziran 2026 A | 19.848 | 0 | 0 | $0 |
| Cynthia Smith | Yönetim kurulu üyesi | 18 Haziran 2026 A | 15.230 | 0 | 0 | $0 |
| Jacqualyn A Fouse | Yönetim kurulu üyesi | 18 Haziran 2026 A | 154.156 | 0 | 0 | $0 |
| Kaye I Foster-Cheek | Yönetim kurulu üyesi | 18 Haziran 2026 A | 10.284 | 0 | 0 | $0 |
| Jeffrey D Capello | Yönetim kurulu üyesi | 18 Haziran 2026 A | 10.865 | 0 | 0 | $0 |
| David P Schenkein | Yönetim kurulu üyesi | 20 Haziran 2024 A | 126.242 | 0 | 0 | $0 |
| Paul J Clancy | Yönetim kurulu üyesi | 21 Haziran 2022 A | 6.549 | 0 | 0 | $0 |
| John Maraganore | Yönetim kurulu üyesi | 21 Haziran 2022 A | 30.028 | 0 | 0 | $0 |
| Ian T Clark | Yönetim kurulu üyesi | 20 Mayıs 2022 M | 6.549 | 0 | 0 | $0 |
| Lewis Clayton Cantley Jr. | Yönetim kurulu üyesi | 07 Aralık 2017 S | 79.515 | 0 | 0 | $0 |
| Robert Nelsen | Yönetim kurulu üyesi | 06 Mart 2017 S | 0 | 0 | 0 | $0 |
| Douglas G. Cole | Yönetim kurulu üyesi | 10 Ağustos 2016 J | 2.778 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | Yönetim kurulu üyesi | 21 Haziran 2016 A | 101.009 | 0 | 0 | $0 |
| Perry A Karsen | Yönetim kurulu üyesi | 23 Haziran 2015 A | · | 0 | 0 | $0 |
| Kevin P Starr | Yönetim kurulu üyesi | 19 Şubat 2015 J | 184.386 | 0 | 0 | $0 |
| Celgene European Investment Co LLC | 10% sahip | 16 Aralık 2014 P | 1.231.778 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 43 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,40% | 46.067 NS | 31 Temmuz 2026 | N-PORT |
| HAPS · Harbor ETF Trust | 0,82% | 46.575 NS | 31 Temmuz 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,50% | 3.546 SH | 02 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,41% | 67.945 NS | 31 Temmuz 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,32% | 139.210 NS | 31 Temmuz 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,22% | 17.481 SH | 02 Ekim 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 119.054 SH | 02 Ekim 2026 | Günlük |
| IBB · iShares Trust | 0,14% | 425.302 SH | 11 Eylül 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,13% | 48.730 SH | 19 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,13% | 4.219 SH | 02 Ekim 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,12% | 928 NS | 31 Temmuz 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,10% | 47.013 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 340.226 SH | 19 Ağustos 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 12.610 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,07% | 1.511.496 SH | 11 Eylül 2026 | Günlük |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,07% | 15.124 NS | 31 Temmuz 2026 | N-PORT |
| ESML · iShares Trust | 0,06% | 50.007 SH | 11 Eylül 2026 | Günlük |
| VBK · VANGUARD INDEX FUNDS | 0,06% | 788.655 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,06% | 28.271 NS | 31 Temmuz 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 192.387 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,04% | 10.228 SH | 11 Eylül 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,03% | 5.807 NS | 31 Temmuz 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,03% | 1.364.364 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,03% | 167.169 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 26.897 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 683.802 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,02% | 3.364 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 3.639 SH | 19 Ağustos 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,01% | 148.210 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 9.209 NS | 31 Temmuz 2026 | N-PORT |
| IWO · iShares Trust | 0,01% | 31.737 SH | 11 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,01% | 4.553 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 17.627 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 16.716 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 76.792 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 17.217 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.890.189 SH | 19 Ağustos 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 46.943 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.834 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,00% | 13.097 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 521.555 SH | 11 Eylül 2026 | Günlük |
| ISCB · iShares Trust | · | 2.551 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 5.020 SH | 11 Eylül 2026 | Günlük |
AGIO Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 16 analist
AL
Medyan hedef
$44.50
+39,9%
5 31,2%
Güçlü Al
7 43,8%
Al
4 25,0%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
8 analist · 2026-09-27Ortalama hedef $46.25 +45,4%
← Tüm hedeflerin altında
Mevcut fiyat $31.80
Düşük$32.00
Ortalama$46.25
Yüksek$73.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | · |
| GENB | · | · | · | · | · | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Tem 30, 2026